Source: International Congress 2014 – Rationale behind respiratory drug development
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Haidl, G. Scheuch, C. Kietzig, D. Kappeler, R. Cloes (Schmallenberg-Grafschaft, Gemuenden/Wohra, Gauting, Limburg/Lahn, Germany). Comparison of the particle size distribution of fluticasone propionate/formoterol and beclometasone/formoterol MDI using laser diffraction. Eur Respir J 2014; 44: Suppl. 58, 939

Member's Comments

No comment yet.

Related content which might interest you: Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI) Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Are extra-fine particles from dry powder inhalers likely to improve lung deposition? Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Are ultrafine particle inhalers, better for patients with small airway involvement? Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 The performance of a new vibrating mesh prototype nebulizer for inhaled biodrugs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques Year: 2016 Effects of combining tiotropium and salmeterol/fluticasone propionate on airway dimensions in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Comparative effectiveness analysis: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate vs fluticasone propionate with spacer in children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Device handling study of a novel fluticasone propionate/formoterol breath-triggered inhaler Source: International Congress 2016 – Pulmonary drug delivery Year: 2016